Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older.

NCT06237296 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT06237296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06237296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older.
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 1
Overall status
Completed
Start date
January 23, 2024
Completion date
February 11, 2025
Enrollment
558 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, metapneumovirus infection, respiratory syncytial virus infection